Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
$8.41
-$0.26(-3.11%)
At close: 4:00 PM EST
$8.41
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.01M
Market Cap
$399.92M
Enterprise Value$621.41M
Total Cash (Recent Filing)$274.20M
Total Debt (Recent Filing)$268.14M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Mar 03, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding50,623,085
10 Day Avg. Volume989,449
30 Day Avg. Volume1,008,726
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.47
Price to Sales (P/S)4.59
P/FCF Ratio-2.18
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit7.71
Enterprise Value/Ebitda-5.18
Forecast
1Y Price Target
$32.89Price Target Upside291.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySustained functional improvements in Duchenne patients treated with the lead gene therapy support the potential for an accelerated regulatory filing and bolster the case for future approval.
Commercial OpportunityPotential first-in-class approval for the Hunter syndrome candidate, combined with company-led manufacturing and a possible Priority Review Voucher, could provide meaningful commercial upside and strengthen financial prospects.
Manufacturing CapabilityIn-house, state-of-the-art manufacturing with high-purity production and full fill-finish capability enables faster development timelines, lower dosing strategies, and capacity to supply commercial demand with attractive cost of goods.
Bears Say
Binary Trial-driven RiskHeavy reliance on key trial readouts and regulatory decisions produces a binary outcome profile that can lead to sharp stock swings and heightened investor risk.
Regulatory UncertaintyA Complete Response Letter citing uncertainty about target population, external controls, and surrogate endpoints, together with clinical holds on related programs, creates ambiguity around resubmission pathways and may delay regulatory review.
Safety ConcernsIdentification of an intracranial tumor in a trial participant and signals of viral vector integration near a cancer-related gene raise unresolved safety concerns that could limit program progression or require label restrictions.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $16.19 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $399.92M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Mar 03, 2026 which is in 10 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Nov 06, 2025. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.282 by $0.082.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -0.96.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,623,085 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.282. Following the earnings report the stock price went down -3.79%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.89 (291.08% Upside)
$32.89 (291.08% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 119.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.73%
12-Months-Change
Fundamentals
Return on Equity
-76.88%
Trailing 12-Months
Asset Growth
1.17%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and achievements in clinical development and financial positioning. However, there are regulatory challenges and uncertainties, particularly concerning international approvals and the use of external controls. Despite these challenges, the overall sentiment leans positive due to strong pipeline advancements and financial stability.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$32.89
▲(291.08% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.42% Insiders
19.07% Mutual Funds
8.85% Other Institutional Investors
48.40% Public Companies and Individual Investors